Oral Administration of Bifidobacterium longum Ameliorates Influenza Virus Infection in Mice

Iwabuchi, Noriyuki; Xiao, Jin‐zhong; Yaeshima, Tomoko; Iwatsuki, Keiji

doi:10.1248/bpb.34.1352

Cited by 61 publications

(41 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our hypothesis, some previous studies reported that administration of probiotics showed reduction in pulmonary virus titres at the same time as alleviation of clinical symptoms during the later stages of IFV infection (Iwabuchi et al . ; Kawase et al . ; Goto et al .…”

Section: Resultsmentioning

confidence: 99%

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Waki¹,

Yajima²,

Suganuma³

et al. 2013

Lett Appl Microbiol

View full text Add to dashboard Cite

Significance and Impact of the Study: This study demonstrated that oral administration of Lactobacillus brevis KB290 (KB290), a probiotic strain derived from a Japanese traditional pickle, could protect against influenza virus (IFV) infection in mice. Our results demonstrated that continual intake of KB290 for 14 days prior to IFV infection alleviated clinical symptoms such as loss of body weight and deterioration in observational physical conditions induced by the infection. The beneficial effects of KB290 consumption may have been elicited by the long-lasting enhancement of interferon-a production and the augmentation of IFV-specific immunoglobulin A production. AbstractLactobacillus brevis KB290 (KB290), isolated from a traditional Japanese pickle 'Suguki', has been reported to have immunomodulatory effects. We investigated whether oral administration of KB290 has protective effects against influenza virus (IFV) infection in mice. After 14 days of administration of lyophilized KB290 suspended in phosphate-buffered saline by oral gavage, BALB/c mice were intranasally infected with 2 9 MLD 50 (50% mouse lethal dose) of IFV A/PR/8/34 (H1N1). Prophylactically administered KB290 significantly alleviated the loss of body weight and the deterioration in observational physical conditions induced by the infection. In addition, 7 days after infection, the levels of IFV-specific immunoglobulin (Ig)A in bronchoalveolar lavage fluid were significantly increased in mice fed KB290 compared with controls. Moreover, there was a significant elevation of serum interferon (IFN)-a in KB290 group mice, even at three and 7 days after infection, despite the administration of KB290 being stopped before IFV infection. Our results demonstrated that oral administration of KB290 before infection could alleviate IFV-induced clinical symptoms. Alleviation of clinical symptoms by KB290 consumption may have been induced by long-lasting enhancement of IFN-a production and the augmentation of IFV-specific IgA production.

show abstract

Section: Resultsmentioning

confidence: 99%

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Waki¹,

Yajima²,

Suganuma³

et al. 2013

Lett Appl Microbiol

View full text Add to dashboard Cite

show abstract

“…Other studies emphasized the importance of IFN-γ production and NK cells activation for the protective effect of immunobiotics against influenza infection (55–57). Earlier studies with the known probiotic strain Lactobacillus casei Shirota clearly demonstrated the capacity of this bacterium to stimulate NK cells activity and cellular immunity in the respiratory tract.…”

Section: Improvement Of Respiratory Anti-viral Immunity With Immunobimentioning

confidence: 99%

Modulation of Respiratory TLR3-Anti-Viral Response by Probiotic Microorganisms: Lessons Learned from Lactobacillus rhamnosus CRL1505

Kitazawa

Villena

2014

Front. Immunol.

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness in infants and young children. Host immune response is implicated in both protective and immunopathological mechanisms during RSV infection. Activation of Toll-like receptor (TLR)-3 in innate immune cells by RSV can induce airway inflammation, protective immune response, and pulmonary immunopathology. A clear understanding of RSV–host interaction is important for the development of novel and effective therapeutic strategies. Several studies have centered on whether probiotic microorganisms with the capacity to stimulate the immune system (immunobiotics) might sufficiently stimulate the common mucosal immune system to improve defenses in the respiratory tract. In this regard, it was demonstrated that some orally administered immunobiotics do have the ability to stimulate respiratory immunity and increase resistance to viral infections. Moreover, during the last decade scientists have significantly advanced in the knowledge of the cellular and molecular mechanisms involved in the protective effect of immunobiotics in the respiratory tract. This review examines the most recent advances dealing with the use of immunobiotic bacteria to improve resistance against viral respiratory infections. More specifically, the article discuss the mechanisms involved in the capacity of the immunobiotic strain Lactobacillus rhamnosus CRL1505 to modulate the TLR3-mediated immune response in the respiratory tract and to increase the resistance to RSV infection. In addition, we review the role of interferon (IFN)-γ and interleukin (IL)-10 in the immunoregulatory effect of the CRL1505 strain that has been successfully used for reducing incidence and morbidity of viral airways infections in children.

show abstract

“…Some selected Lactobacillus and Bifidobacterium strains have been reported to be effective against IFV via various immunological effects, for example, augmentation of NK cell activity in the spleen and lung (Hori et al 2002;Yasui et al 2004;Harata et al 2010Harata et al , 2011Izumo et al 2010), suppression of IL-6 and IFN-c levels in the lungs (Iwabuchi et al 2011) and enhancement of the production of anti-IFV IgG in serum (Yasui et al 1999), anti-IFV IgA in serum and bronchoalveolar lavage fluid (Kobayashi et al 2011) and serum type I IFN (Maeda et al 2009). Furthermore, it has been reported that there are huge differences in protective effects for IFV infection depending on the administration routes (intranasally or orally) and the viable status of bacteria (live or dead) (Youn et al 2012).…”

Section: Discussionmentioning

confidence: 99%

Oral administration of milk fermented with Lactococcus lactis subsp. cremoris FC protects mice against influenza virus infection

Maruo¹,

Gotoh²,

Nishimura

et al. 2012

Letters in Applied Microbiology

View full text Add to dashboard Cite

Aims: To evaluate the protective effects of oral administration of milk fermented with a Lactococcus strain against influenza virus (IFV) infection in a mouse model. Methods and Results: Milk fermented with exopolysaccharide‐producing Lactococcus lactis subsp. cremoris (L. cremoris) FC was orally administered to BALB/c mice for 12 days. Mice were intranasally infected with IFV A/New Caledonia/20/99 (H1N1) on day 8, and survival was determined for 14 days after IFV infection. Survival rate and body weight loss after IFV infection in the L. cremoris FC fermented milk‐administered group were significantly improved compared with those in the control group. In the unfermented milk‐administered group, survival rate was not improved, whereas body weight loss was slightly improved compared with that in the control group. The mean virus titre in the lung of the L. cremoris FC fermented milk‐administered group 3 days after infection was significantly decreased compared with that in the control group. Conclusions: These results suggest that oral administration of milk fermented with L. cremoris FC protects mice against IFV infection. Significance and Impact of the Study: These results demonstrate that oral administration of milk fermented with exopolysaccharide‐producing Lactococcus strains might protect host animals against IFV infection.

show abstract

Oral Administration of Bifidobacterium longum Ameliorates Influenza Virus Infection in Mice

Cited by 61 publications

References 16 publications

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Modulation of Respiratory TLR3-Anti-Viral Response by Probiotic Microorganisms: Lessons Learned from Lactobacillus rhamnosus CRL1505

Oral administration of milk fermented with Lactococcus lactis subsp. cremoris FC protects mice against influenza virus infection

Contact Info

Product

Resources

About